0OO9 Stock Chart & Stats
€44.35
€0.63(1.43%)
At close: 4:00 PM EDT
€44.35
€0.63(1.43%)
Day’s Range― - ―
52-Week Range€35.13 - €52.82
Previous CloseN/A
Volume1.23K
Average Volume (3M)162.35K
Market Cap
€25.84B
Enterprise Value€33.35K
Total Cash (Recent Filing)€1.28B
Total Debt (Recent Filing)€11.42B
Price to Earnings (P/E)16.8
Beta1.03
Next Earnings
Nov 04, 2026EPS Estimate
0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.75
Shares Outstanding563,237,300
10 Day Avg. Volume142,299
30 Day Avg. Volume162,347
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.44
Price to Sales (P/S)1.21
P/FCF Ratio23.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€55.28Price Target Upside24.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)3.66
Revenue Forecast (FY)€23.73B
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryRevenue has recovered from the weak 2023 base and is growing again, supporting operating leverage across healthcare services and products. The recurring nature of dialysis and care demand provides a durable foundation for continued revenue stability.
Profitability RecoveryThe return to positive net profitability and solid operating margins indicates meaningful recovery in business performance. Sustained margins across care delivery, pharmaceuticals and medical products can improve earnings resilience if operational improvements persist.
DeleveragingMaterial deleveraging reduces financial risk, interest burden and refinancing dependence while increasing strategic flexibility. A sizable equity base and improved leverage position Fresenius to invest in its healthcare operations and absorb industry pressures.
Bears Say
Weakening Free Cash FlowPositive cash generation is being weakened by a declining free-cash-flow trend. If this persists, Fresenius may have less capacity for debt reduction, reinvestment and shareholder distributions, reducing confidence that reported earnings fully convert into financial strength.
Soft Cash ConversionLow conversion of accounting earnings into free cash flow suggests that working-capital needs or capital expenditure remain significant. This can constrain funding flexibility and make the profitability recovery less durable until conversion improves.
Incomplete Profitability NormalizationAlthough profitability has recovered, margins and returns have not fully regained earlier levels. This indicates that operating efficiency or asset productivity still has room to improve, leaving the recovery exposed to cost pressure and execution risk.
Fresenius SE & Co. KGaA News
0OO9 FAQ
What was Fresenius SE & Co. KGaA’s price range in the past 12 months?
Fresenius SE & Co. KGaA lowest share price was €35.13 and its highest was €52.82 in the past 12 months.
What is Fresenius SE & Co. KGaA’s market cap?
Fresenius SE & Co. KGaA’s market cap is €25.84B.
When is Fresenius SE & Co. KGaA’s upcoming earnings report date?
Fresenius SE & Co. KGaA’s upcoming earnings report date is Nov 04, 2026 which is in 68 days.
How were Fresenius SE & Co. KGaA’s earnings last quarter?
Fresenius SE & Co. KGaA released its earnings results on Aug 04, 2026. The company reported €0.83 earnings per share for the quarter, missing the consensus estimate of €0.889 by -€0.059.
Is Fresenius SE & Co. KGaA overvalued?
According to Wall Street analysts Fresenius SE & Co. KGaA’s price is currently Undervalued.
Does Fresenius SE & Co. KGaA pay dividends?
Fresenius SE & Co. KGaA does not currently pay dividends.
What is Fresenius SE & Co. KGaA’s EPS estimate?
Fresenius SE & Co. KGaA’s EPS estimate is 0.78.
How many shares outstanding does Fresenius SE & Co. KGaA have?
Fresenius SE & Co. KGaA has 563,237,300 shares outstanding.
What happened to Fresenius SE & Co. KGaA’s price movement after its last earnings report?
Fresenius SE & Co. KGaA reported an EPS of €0.83 in its last earnings report, missing expectations of €0.889. Following the earnings report the stock price went down -0.692%.
Which hedge fund is a major shareholder of Fresenius SE & Co. KGaA?
Currently, no hedge funds are holding shares in GB:0OO9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius SE & Co. KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€55.28 (24.65% Upside)
€55.28 (24.65% Upside)
Insider Transactions
Bought Shares
Worth €197.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.67%
12-Months-Change
Fundamentals
Return on Equity
2.29%
Trailing 12-Months
Asset Growth
1.27%
Trailing 12-Months
Company Description
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.
0OO9 Stock 12 Month Forecast
Average Price Target
€55.28
▲(24.65% Upside)
Technical Analysis
CompuGroup Medical
―
Draegerwerk AG & Co. KGaA
―
Fresenius Medical Care AG & Co. KGaA
―
MEDICLIN
―
RHON-KLINIKUM AG
―








